Search

Displaying results 221 - 230 of 288 in total
  1. Drug

    Abaloparatide

    go.drugbank.com/drugs/DB05084
    ApprovedInvestigational

    [L740] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended abaloparatide be granted marketing authorization in Europe [L43552] and the drug was fully authorized … by the European Commission on December 19, 2022.

  2. Drug

    Selpercatinib

    go.drugbank.com/drugs/DB15685
    ApprovedInvestigational

    [L13604] Selpercatinib is also approved by the European Commission.

  3. Drug

    Darvadstrocel

    go.drugbank.com/drugs/DB16581
    ApprovedInvestigationalWithdrawn

    [L39759] It is the first mesenchymal stem cell therapy approved in Europe for this therapeutic indication. … [A244524] Darvadstrocel was first approved by the European Commission on March 23, 2018, under the brand name Alofisel.

  4. Drug

    Talquetamab

    go.drugbank.com/drugs/DB16678
    ApprovedInvestigational

    Talquetamab is a IgG4-PAA bispecific G protein-coupled receptor class C group 5 member D (GPRC5D)-directed CD3 T-cell engager. It consists of two arms - anti-GPRC5D and anti-CD3 arms - linked by two interchain disulfide bonds, each arm c...

  5. Drug

    Tezepelumab

    go.drugbank.com/drugs/DB15090
    ApprovedInvestigational

    [L39504] Tezepelumab was also approved by the European Commission on September 19, 2022.[L44712]

  6. Drug

    Nicoboxil

    go.drugbank.com/drugs/DB12911
    ApprovedWithdrawn

    Such combination topical analgesics are only available for purchase and use (for humans) in some parts of Europe and Asia, like Germany and Australia [F11, F16]. … continued interest in the medication(s) given its demonstrated efficacy, safety, and capability to be used as an alternative musculoskeletal pain therapy option with less systemic side effects when compared

  7. Drug

    Brexanolone

    go.drugbank.com/drugs/DB11859
    ApprovedInvestigational

    brexanolone may also be undergoing clinical trials to investigate its abilities to treat super-refractory status epilepticus, it appears that some such studies have failed to meet primary endpoints that compare

  8. Drug

    Flupirtine

    go.drugbank.com/drugs/DB06623
    Investigational

    It was approved for the treatment of pain in 1984 in Europe. It is not approved for use in the U.S. or Canada, but is currently in phase II trials for the treatment of fibromyalgia.

  9. Drug

    Elranatamab

    go.drugbank.com/drugs/DB15395
    ApprovedInvestigational

    [L47820] Elranatamab was also approved by the European Commission on December 8, 2023.[L50437]

  10. Drug

    Nirsevimab

    go.drugbank.com/drugs/DB16258
    ApprovedInvestigational

    [A254691] This is due to a modification in the Fc region of nirsevimab that grants it a longer half-time compared to typical monoclonal antibodies. … [L44146,A254571] Compared to [palivizumab], another anti-RSV antibody, nirsevimab shows greater potency at reducing pulmonary viral loads in animal models.